Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:42:35.003Z.
Calculation as of: 2026-10-06T20:42:35.003Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$857.16M
EV/FCF Ratio
N/A
TTM Avg
241.82x
3Y Avg
97.19x
5Y Avg
51.67x
Market Cap
$884.97M
EV/FCF Ratio
N/A
TTM Avg
14.36x
3Y Avg
10.42x
5Y Avg
10.42x
Market Cap
$887.99M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$853.13M
EV/FCF Ratio
10.48x
TTM Avg
9.71x
3Y Avg
14.43x
5Y Avg
26.15x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $870.81M | N/A | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | N/A | 241.82x | 97.19x | 51.67x |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | N/A | 14.36x | 10.42x | 10.42x |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $887.50M | 11.90x | 13.69x | 60.52x | 99.98x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 10.48x | 9.71x | 14.43x | 26.15x |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 197.16x | 197.16x | 197.16x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
